Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Gains from Investment Securities (2021 - 2025)

Rxo (RXO) has disclosed Gains from Investment Securities for 4 consecutive years, with -$49.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$49.0 million, compared with a TTM value of -$11.0 million through Dec 2025, changed N/A, and an annual FY2025 reading of -$11.0 million, changed N/A over the prior year.
  • Gains from Investment Securities was -$49.0 million for Q4 2025 at Rxo, down from $44.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $46.0 million in Q3 2022 and bottomed at -$49.0 million in Q4 2025.
  • Average Gains from Investment Securities over 4 years is $200000.0, with a median of $2.0 million recorded in 2023.
  • Peak annual rise in Gains from Investment Securities hit 1566.67% in 2025, while the deepest fall reached 2400.0% in 2025.
  • Year by year, Gains from Investment Securities stood at -$46.0 million in 2022, then soared by 104.35% to $2.0 million in 2023, then tumbled by 250.0% to -$3.0 million in 2024, then plummeted by 1533.33% to -$49.0 million in 2025.
  • Business Quant data shows Gains from Investment Securities for RXO at -$49.0 million in Q4 2025, $44.0 million in Q3 2025, and -$23.0 million in Q2 2025.